Cis-Ormeloxifene | CAS 51423-20-2 - Request Quote
Cis-Ormeloxifene
| SZ CAT No: | SZ-O027006 |
| CAS No | 51423-20-2 |
| Mol.F. | C30H35NO3 |
| Mol.Wt. | 457.6 |
| Inv. Status | Under QC Approval |
| Rel. CAS No | 51423-19-9 (HCl salt) |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Cis-Ormeloxifene is chemically rel-1-(2-(4-((3R,4S)-7-methoxy-2,2-dimethyl-3-phenylchroman-4-yl)phenoxy)ethyl)pyrrolidine. Cis-Ormeloxifene is supplied with detailed characterization data compliant with regulatory guideline. Cis-Ormeloxifene can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ormeloxifene.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 51423-20-2
Purchase 51423-20-2
Order 51423-20-2
Enquire 51423-20-2
price of 51423-20-2
51423-20-2 Supplier
51423-20-2 Manufacturer
51423-20-2 Exporter
buy high quality Cis-Ormeloxifene
Purchase Cis-Ormeloxifene
Cis-Ormeloxifene suppliers
Cis-Ormeloxifene manufacturers
Cis-Ormeloxifene price
Order Cis-Ormeloxifene
Enquire Cis-Ormeloxifene
Cis-Ormeloxifene cost
Cis-Ormeloxifene Supplier
Cis-Ormeloxifene Distributor
Cis-Ormeloxifene for Method Validation
Ormeloxifene Reference Standard
Cis-Ormeloxifene for ANDA Filing
Cis-Ormeloxifene for Forced Degradation Studies
Cis-Ormeloxifene Identification Standards
Cis-Ormeloxifene for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


